These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7713468)

  • 1. [How reliable are tumor markers? Only the experienced physician knows how to apply these diagnostic aids sensibly].
    Janssen K
    Fortschr Med; 1995 Feb; 113(4):49-51. PubMed ID: 7713468
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of predictive values of tumor markers.
    Roulston JE
    Methods Mol Med; 2004; 97():13-27. PubMed ID: 15064482
    [No Abstract]   [Full Text] [Related]  

  • 3. Organ preservation in head and neck cancer: are there reliable molecular predictors?
    Hanna EY
    Curr Oncol Rep; 2001 Jan; 3(1):43-4. PubMed ID: 11123868
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunohistochemical studies].
    Dietz A; Bosch F
    HNO; 2004 May; 52(5):468-70. PubMed ID: 15088091
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities].
    Nepomniashchaia EM; Gusareva MA; Petrov SV
    Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein and hepatocellular carcinoma.
    Colli A; Fraquelli M; Conte D
    Am J Gastroenterol; 2006 Aug; 101(8):1939; author reply 1940-1. PubMed ID: 16928257
    [No Abstract]   [Full Text] [Related]  

  • 8. [Criteria for the use of tumor markers. 1: Quality assurance--characteristics of the most important tumor markers].
    Fateh-Moghadam A; Stieber P
    Fortschr Med; 1996 Feb; 114(6):30-3. PubMed ID: 8900526
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standards for reporting prognostic tumor marker studies.
    Alonzo TA
    J Clin Oncol; 2005 Dec; 23(36):9053-4. PubMed ID: 16301590
    [No Abstract]   [Full Text] [Related]  

  • 11. [Usefulness of the tumor markers in the diagnosis of idiopathic deep venous thrombosis associated cancer].
    Enguídanos MJ; Todolí JA; Saro E; Salvador G; Villar J; Gómez-Biedma S; Micó L; Calabuig JR
    An Med Interna; 2002 Nov; 19(11):561-6. PubMed ID: 12522891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of soluble transferrin receptors study in hepatocellular carcinoma with underlying cirrhosis.
    Mehta R; Suvarna D; Mustafa CP; Sadasivan S
    Indian J Cancer; 2005; 42(4):215. PubMed ID: 16391443
    [No Abstract]   [Full Text] [Related]  

  • 13. [Criteria for using tumor markers. 2: Indications and interpretation].
    Fateh-Moghadam VA; Stieber P
    Fortschr Med; 1996 Mar; 114(7):38-40. PubMed ID: 8900968
    [No Abstract]   [Full Text] [Related]  

  • 14. Back to the drawing board on immunohistochemistry and predictive factors.
    Henson DE
    J Natl Cancer Inst; 2005 Dec; 97(24):1796-7. PubMed ID: 16368935
    [No Abstract]   [Full Text] [Related]  

  • 15. Biomarker boom slowed by validation concerns.
    Benowitz S
    J Natl Cancer Inst; 2004 Sep; 96(18):1356-7. PubMed ID: 15367567
    [No Abstract]   [Full Text] [Related]  

  • 16. Breast cancer: what's HER-2/neu got to do with it?
    Lenahan C; Dennis C; Isakovich NV; Pories SE
    Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential diagnosis in immunohistochemistry with Bayes theorem.
    Vollmer RT
    Am J Clin Pathol; 2009 May; 131(5):723-30. PubMed ID: 19369634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant analysis of salivary tumor markers--a new diagnostic tool for oral cancer.
    Nagler R; Bahar G; Shpitzer T; Feinmesser R
    Clin Cancer Res; 2006 Jul; 12(13):3979-84. PubMed ID: 16818695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.